Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : DRW Venture Capital LLC
Deal Size : $10.8 million
Deal Type : Financing
DelSiTech Closes EUR 10 Million Financing Round for Drug Delivery Technology
Details : Proceeds will support clinical development of DST1308, using a silica-based drug delivery platform, for Chronic Hepatitis B.
Brand Name : DST1308
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : DRW Venture Capital LLC
Deal Size : $10.8 million
Deal Type : Financing
Lead Product(s) : DST-2105
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DST-2105 is based on DelSiTech's Silica Matrix formulation technology which enables the once daily administration of eye drops in the cul-de-sac of the eye, which is investigated for relieving dry eye symptoms.
Brand Name : DST-2105
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : DST-2105
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Details : DelSiTech will develop long-acting injectable formulations ensuring slow release of HIV vaccine. Silica Matrix technology provides controlled long-acting drug release w/o interfering with its therapeutic functions and is compatible with small molecules a...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : IVERIC bio
Deal Size : Undisclosed
Deal Type : Agreement
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
Details : As part of Iveric Bio’s lifecycle expansion plan for Zimura (avacincaptad pegol), the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).
Brand Name : Zimura
Molecule Type : Large molecule
Upfront Cash : $1.2 million
July 05, 2022
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : IVERIC bio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Optifye Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Controlled release of dexamethasone eye drops, based on DelSiTech™ Silica Matrix technology, is a revolutionary eye drop product that is applied as a single drop, once daily under the eye lid which maintains therapeutic drug concentration in the eye.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Optifye Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?